Phase 2, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study of INV-102 Ophthalmic Solution in Patients With Acute Infectious Keratoconjunctivitis
Latest Information Update: 27 Sep 2024
At a glance
- Drugs INV-102-Invirsa (Primary)
- Indications Keratoconjunctivitis; Ocular hyperaemia
- Focus Therapeutic Use
- Sponsors Invirsa
Most Recent Events
- 19 Sep 2024 Status changed from recruiting to completed.
- 14 May 2024 Planned End Date changed from 1 Aug 2024 to 1 Jun 2024.
- 06 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Aug 2024.